EBS - Altimmune: Suppressed Immature Or Dormant?
2018 has been a volatile year for Altimmune (ALT) from start to finish. The company experienced mixed results in clinical trials as well as changes management positions. Unfortunately, the share price has taken the brunt of the losses and has gained little from the wins. After a reverse split in September, the stock went parabolic due to a low float run; then it crashed due to subsequent share offerings. Currently, the share price appears to have stabilized around the $3.00 mark and the chart appears to be ready for a move. However, it